Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL | Chemotherapy | Drug | Race | TIMEPOINT | Tamoxyfen | Taxane |
---|---|---|---|---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1065 | Peak area | Case | Y | Exemestane | White | Baseline | Y | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1163 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1383 | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1790 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 2349 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 3068 | Peak area | Control | N | Letrozole | White | Baseline | Y | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 3885 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 5196 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 14368 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 20459 | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |